Table 1.
Classification of literature based on diabetogenic effect of immunosuppressive drugs.
Table 2.
Classification of literature based on the impact of risk factors on hyperglycemia and NODAT.
Table 3.
Description of abbreviations used in this study.
Table 4.
Demographic and baseline characteristics of patients at the time of transplant.
Table 5.
Percentage of patients satisfying the criteria.
Fig 1.
Number of patients who used immunosuppressive drugs at months 1, 4, and 12.
Such patients are further classified as having hyperglycemia (HG) or not at that specific time points.
Table 6.
Tacrolimus goals and achieved levels (average trough level) at months 1, 4, and 12.
Table 7.
Effect of immunosuppressive drugs on hyperglycemia: The results of two statistical inference methods (numbers in bold represent statistically significant covariates at 95% confidence level).
Table 8.
Description of groups formed by risk factors.
Fig 2.
Kaplan-Meier survival curves: Cumulative probability of experiencing hyperglycemia (%) as a result of having different average trough levels of tacrolimus: ≤10 mg/dL vs. >10 mg/dL. In all parts (A)-(K), the P-value by the Logrank test is <0.0001. (+ represents censored events.).
(A) Unadjusted (univariate) analysis. (B) Adjusted analysis with age. (C) Adjusted analysis with race. (D) Adjusted analysis with gender. (E) Adjusted analysis with BMI. (F) Adjusted analysis with BP. (G) Adjusted analysis with Chol. (H) Adjusted analysis with HDL. (I) Adjusted analysis with LDL. (J) Adjusted analysis with UA. (K) Adjusted analysis with TG.
Table 9.
Risk factors that affect the incidence of hyperglycemia.
Table 10.
Effect of inpatient period on hyperglycemia incidence.